Page 144 - CW E-Magazine (10-9-2024)

Pharmaceuticals IMPORT \ EXPORT DATA
Any Chapter Rs.500 per month
PRODUCT LAUNCH CHEMLINK SOFTWARE
MUMBAI
Bharat Biotech launches affordable oral cholera vaccine Mr. Bhavin Patel

8469140555
Bharat Biotech International Ltd. According to the company, a multi- While Hillchol is not the fi rst cholera chemlinksoft@gmail.com
(BBIL) has launched its Oral Cholera stage clinical evaluation process culmi- vaccine, it is novel in some crucial
Vaccine (OCV), Hillchol. nating in a Phase III study confi rmed ways. It can protect against a new strain MANuFACTuRERS / SuPPLIERS OF
ALCOHOL DENATuRANTS / BITTERANTS
the vaccine’s safety, immunogenicity, of the disease. It also offers a simpli-  ACETALDEHYDE
The launch of the vaccine is the and non-inferiority to existing OCVs, fi ed production process, which makes  CROTONALDEHYDE
result of extensive international collabo- establishing its potential for widespread it “cheaper” than those available in the  DENATONIUM BENZOATE
ration between Hilleman Laboratories, public health use. market now, BBIL said.  DENATONIUM SACCHARIDE
 PYRIDINE BASE
Bharat Biotech, the University of Gothen-  CAOUTCHOUCINE
burg, and Gotovax AB. The vaccine Hyderabad-based Bharat Biotech Global demand for OCVs exceeds The Lakshmiji Organics Pvt. Ltd.
Sitapur, UP. Mob.: 09322661064
was developed by BBIL under licence received all necessary approvals from 100-million doses per annum. There is a Email: organics@lakshmiji.com / loplstp@gmail.com
from Hilleman Laboratories, funded by the Indian drug regulators to produce shortage of about 40-million doses now,
Merck, USA and Wellcome Trust, UK. and market it in the domestic market. and Bharat Biotech hopes to bridge this
“Based on our national approvals, the gap with Hillchol. Currently, only one Manufacturer of :
“We want to work on neglected process for obtaining pre-qualifi cation manufacturer supplies OCVs worldwide. • Sodium-2-Ethyl Hexanoate
diseases which are mainly in Asia and for the World Health Organization • Potassium-2-Ethyl Hexanoate
Africa. One of the contributions in this (WHO) will be taken up,” Dr. Ella said. The two-dose Hillchol vaccine is • Barbituric Acid
regard is this cholera vaccine,” said “The WHO has a target of eradicating administered with a gap of 14 days
Dr. Krishna Ella, Executive Chairman, Cholera by 2030, and we also want to between the two doses and is suitable • 4-N,N-Dimethyl Amino Benzaldehyde
BBIL. be a part of it,” he added. for all those older than one year. • Ammonia Liquor - L R Grade
• IPA + HCl 25%
MANAGEMENT VISION • T-Butyl Chloro Acetate (TBCA)
Cipla outlines new focus areas for the future FERGUSON CHEMICALS

Mumbai-based drug fi rm, Cipla, has Newer areas as HIV, AIDS, and TB and work in the Plot No. 6217/1,2 & 3, G.I.D.C. Estate,
reiterated that the 2 percent-odd stake The company’s management also fi ght against antimicrobial resistance, Ankleshwar - 393 002, Dist.- Bharuch, Guj, India.
sale by promoters earlier this year was informed shareholders about the newer he said. Mr. Vohra added that the com- Email: nalinfc@hotmail.com,
towards philanthropy and social efforts areas it was keen to focus on. pany’s blueprint in fi ve to seven years ferguson9858@gmail.com
of the company. The recent stake sale “is not going to be solely in the area Contact : Mr. Nalin Ramani - 093283 37836 KNS ADI
was towards the stated objectives In his opening remarks, Cipla’s of manufacturing and chemistry as we
“around the area of philanthropy and founder Dr. Y. K. Hamied said, “We are know it today, but also in the world of
around the area of social impact,” Cipla investing in newer devices and in the biology.” CARDKEM PHARMA PVT. LTD. Certified Company by ISO 9001:2015 QMS Standards
Managing Director and Global CEO area of diagnosis, biotech, stem cells, Intermediate of APIs' CAS NO. End Use FINE CHEMICALS CAS NO.
Mr. Umang Vohra said, responding to gene therapy, CART technology and Echoing Dr. Hamied’s plans, he L-proline benzyl ester hydrochloride 16652-71-4
a query during the company’s annual messenger RNA technologies. This, in said, “So we would like to imagine Phenyl Ethyl Chloride 622-24-2 Lisinopril Pyridine Hydrobromide 18820-82-1
Pyridinium bromide per Bromide
39416-48-3
shareholder meeting, held recently. my opinion is in the immediate future Cipla’s core business as being a generic N-Methyl Carbazolone 27387-31-1 Lisinopril Pyridine Hydrochloride 628-13-7
Ondansetron
and will benefi t the company immensely. business and the several other businesses 1,2,3,4-Tetrahydro-4-oxo-carbazole 15128-52-6 Sodium 2-ethylhexanoate (SEHA) 19766-89-3
“This has happened this year and Additionally, we are studying advanced that we are investing in as businesses Bromo-OTBN 114772-54-2 Carvedilol/ Ondansetron Ethyltriphenylphosphonium Bromide (ETPB) 1530-32-1
Losartan
last year also but the main thing is there methods of treatment expanding both of the future. The businesses of the 2-Chloro-5-Nitrobenzoic Acid 2516-96-3 Mesalamine Benzyltriethylammonium chloride (TEBA) 56-37-1
1112-67-0
Tetrabutyl Ammonium Chloride (TBAC)
is no major disruption from this amount manufacturing, marketing and distri- future solely depend on the performance 5-Nitro Salicylic Acid 96-97-9 Mesalamine Triethylamine HCL (TEA HCL) 554-68-7
which the promoters are taking for the bution technologies, using automation of the core businesses because the core 2-[(1-hydroxycyclohexyl)-2-(4-methoxyphenyl)] 93413-76-4 Venlafaxine Hcl 1,3-Dibromo-5,5-Dimethyl Hydantoin (DBDMH) 77-48-5
social efforts for the company,” he added. and digitalisation to achieve our future businesses generate cash, generate acetonitrile Benzyl triphenyl phosphonium chloride (BTPC) 1100-88-5
Tetrabutylammonium bromide (TBAB)
1643-19-2
The statement comes against the goals.” resources that we can then use to Propyl Paraben Sodium 35285-69-9 Tetra Butyl ammonium Hydrogen Sulphate (TBS) 32503-27-8
backdrop of reports last year that deploy in the innovation businesses of Sodium Bromide 7647-15-6
promoters were looking to exit their This would be in addition to their the future.” “We have identifi ed new “We have dedicated facility for custom synthesis & High value speciality products”. Ethyl Bromide 74-96-4
stake, something that has also been efforts in segments including respira- areas in the space of obesity, mental Corporate Office : 2301/02, GIDC Industrial Estate, Ankleshwar - 393 002, Gujarat, INDIA. Iso Butyl Bromide 78-77-3
Ethylene Di Bromide
106-93-4
denied by the promoters. tory medicine, chronic diseases such health and oncology,” he added. Ph : 8866051978 / 8866051980 • Fax No : +91 2646 250052 • Hydrobromic Acid 10035-10-6
Mobile : +91 9723708111 / 9723708112, 9723708119
Email : aniket@cardkem.com, amit@cardkem.com • Web : www.cardkem.com KNS ADI 2 Bromo Propanoic Acid 598-72-1
13/07
144 Chemical Weekly September 10, 2024
Contents Index to Advertisers Index to Products Advertised